|
|
[資源]
EBR - January 2019
The European Biopharmaceutical Review (EBR), is a journal designed to fill a unique position in scientific publishing. Published quarterly, it provides a dedicated platform of communication and information for the pan European biopharmaceutical market across Europe, North America & the rest of the developed world. The editorial covers in-depth articles, case studies, meeting and report reviews written by specialists with "hands-on" experience in the biopharmaceutical industry, traditional multi-national pharmaceutical companies, investment houses and industry-associated governmental, economic and societal bodies. Each quarterly edition examines topical areas of importance across the board of biopharmaceutical research and development, with 'regular feature sections on: Biobusiness, Science and Innovation, Biodiscovery, Biodevelopment, Biomanufacturing plus special focuses on geographic or therapeutic territories. Established in 1997, EBR is now well-recognised for providing beneficial information to players in the bio-industry including entrepreneurial biopharmaceutical and more general life science companies, large pharma companies, supplier groups, regulators, investors, analysts and consultants, thus providing a unique forum for general review of the European life science sector on a regular basis.![EBR - January 2019]()
1503505927.png |
» 本帖附件資源列表
-
歡迎監(jiān)督和反饋:小木蟲僅提供交流平臺,不對該內(nèi)容負(fù)責(zé)。
本內(nèi)容由用戶自主發(fā)布,如果其內(nèi)容涉及到知識產(chǎn)權(quán)問題,其責(zé)任在于用戶本人,如對版權(quán)有異議,請聯(lián)系郵箱:xiaomuchong@tal.com
- 附件 1 : EBR_-_January_2019.pdf
2019-03-18 12:54:13, 8.67 M
» 猜你喜歡
|